Results 41 to 50 of about 48,310 (191)
Many known diseases arise from dysregulated gene expression, and differentially expressed genes can serve as biomarkers to distinguish diseased cells from healthy tissues. In this study, reconfigurable nucleic acid nanoparticles (recNANPs) are introduced that can detect overexpressed cancer biomarkers and subsequently release RNAi inducers to silence ...
Yelixza I. Avila+7 more
wiley +1 more source
Programmed cell death during neuronal development: the sympathetic neuron model. [PDF]
Developing sympathetic neurons of the superior cervical ganglion are one of the best studied models of neuronal apoptosis. These cells require nerve growth factor (NGF) for survival at the time that they innervate their final target tissues during late ...
Ham, J, Kristiansen, M
core +1 more source
Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq+4 more
wiley +1 more source
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi+130 more
core +1 more source
This review highlights recent progress in nanocarriers targeting pattern recognition receptors (PRRs), including Toll‐like and NOD‐like receptors, for enhancing the treatment of bacterial sepsis and related complications. These nanomedicines deliver antibiotics and anti‐inflammatory agents while modulating immune responses.
Eman A. Ismail+3 more
wiley +1 more source
Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2 [PDF]
Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5 ...
Akl, Haidar+18 more
core +3 more sources
Understanding miR‐200c: an Important Player in Resistance to Cancer Treatment
How can one microRNA alter cancer's response to therapy? miR‐200c plays a central role in therapeutic resistance by modulating epithelial‐mesenchymal transition, apoptosis, cancer stemness features, and drug efflux. This review outlines the context‐dependent functions of miR‐200c in various cancers and highlights its potential as both a biomarker and a
Fatma Sanli, Omer Faruk Karatas
wiley +1 more source
The bottom‐up strategy based on multiomics data is used for the SynCom design, and it successfully inhibited F. nucleatum growth and achieved stable colonization in vivo. In addition, it promoted tryptophan metabolism and secondary bile acid conversion, reduced lipid accumulation, relieved microbiome disorder, decreased inflammatory reaction, and ...
Zhongkun Zhou+11 more
wiley +1 more source
Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia [PDF]
Background/Aim. Chronic myeloid leukemia (CML) represents a malignant myeloproliferative disease developed out of pluripotent hematopoietic stem cell that contains the fusion bcr-abl gene. Disorders that occur in the process of apoptosis represent one of
Brajušković Goran+5 more
core +1 more source
CRISPR/Cas9 screening reveals PTPN2 as essential for ALK+ ALCL survival. PTPN2 regulates TFRC to promote PINK1‐PRKN mitophagy. Oral PTPN2 inhibitor ABBV‐CLS‐484 disrupts mitochondrial renewal and blocks TFRC‐mediated mitophagy to exert anti‐tumor activities, supporting clinical development for ALK+ ALCL.
Wei‐Ting Wang+11 more
wiley +1 more source